Evidence map›Paper›PMID 42472098›Full record

ArticleiScience2026

Isotype-switched antibodies originating from tertiary lymphoid structures can antagonize ovarian cancer progression.

Gunjan Mandal, Subir Biswas, Carmen M Anadon, Baishali Tamuli, Ricardo A Chaurio, Luis U Lopez-Bailon, Noah Plappert, Dayan Carrion-Estrada, Jessica A Mine, Chun-Hsiang Lai and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Gunjan MandalTumor Immunology and Immunotherapy, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai 410210, Maharashtra, India.
Subir BiswasTumor Immunology and Immunotherapy, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai 410210, Maharashtra, India.
Carmen M AnadonDepartment of Integrative Immunobiology, Durham, NC 27710, USA.
Baishali TamuliTumor Immunology and Immunotherapy, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai 410210, Maharashtra, India.
Ricardo A ChaurioDepartment of Integrative Immunobiology, Durham, NC 27710, USA.
Luis U Lopez-BailonDepartment of Integrative Immunobiology, Durham, NC 27710, USA.
Noah PlappertDepartment of Integrative Immunobiology, Durham, NC 27710, USA.
Dayan Carrion-EstradaDepartment of Integrative Immunobiology, Durham, NC 27710, USA.
Jessica A MineDepartment of Integrative Immunobiology, Durham, NC 27710, USA.
Chun-Hsiang LaiDepartment of Integrative Immunobiology, Durham, NC 27710, USA.
Angela Per MorenoDepartment of Integrative Immunobiology, Durham, NC 27710, USA.
Joseph JohnsonAnalytic Microscopy Core, Tampa, FL 33612, USA.
Carlos M Moran-SeguraAdvanced Analytical and Digital Laboratory, Tampa, FL 33619, USA.
Bin FangProteomics and Metabolomics Core, Memphis, TN 38163, USA.
Douglas MarchionTissue Core, Tampa, FL 33612, USA.
Neelkamal ChaudharyFlow Cytometry Core, Tampa, FL 33612, USA.
Kathryn L TerryObstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Naoko SasamotoObstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Mary K TownsendDivision of Oncological Sciences, Oregon Health & Science University, Portland, OR 97201, USA.
Jenny O'BrienDepartment of Medicine, Duke School of Medicine, Durham, NC 27710, USA.
Scott J AntoniaDepartment of Medicine, Duke School of Medicine, Durham, NC 27710, USA.
Shelley S TworogerDivision of Oncological Sciences, Oregon Health & Science University, Portland, OR 97201, USA.
Xiaoqing YuDepartment of Biostatistics and Bioinformatics, Tampa, FL 33612, USA.
Paulo C RodriguezDepartment of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Jose R Conejo-GarciaDepartment of Integrative Immunobiology, Durham, NC 27710, USA.

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSNER, BERNARD A · 2000 to 2019
$77.8M
Vascular Leukocytes Influence the Tumor MicroenvironmentR01CA124515 · NCI · WISTAR INSTITUTE · PI Jose R Conejo-Garcia · 2007 to 2026
$7.1M
Stress Pathways in Tumors Drive Global MDSC Activity and Survival through ChopR01CA184185 · NCI · LSU HEALTH SCIENCES CENTER · PI RODRIGUEZ, PAULO CESAR · 2015 to 2019
$1.8M
Inter-metastatic divergency in small cell lung cancer; implications for the design of future immunotherapiesR01CA278907 · NCI · DUKE UNIVERSITY · PI Jose R Conejo-Garcia · 2023 to 2026
$1.5M
Novel immunotherapies using optimized tumor cell-penetrating antibodiesR01CA297896 · NCI · DUKE UNIVERSITY · PI Jose R Conejo-Garcia · 2025 to 2026
$1.2M
OR2H1 is an effective target for CAR T cells in human epithelial tumorsR21CA276205 · NCI · DUKE UNIVERSITY · PI CONEJO-GARCIA, JOSE R · 2023 to 2024
$409k
Spontaneous humoral responses open opportunities for novel immunotherapies against human cancerK99CA266947 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI BISWAS, SUBIR · 2022 to 2023
$215k
NCI NIH HHS K99 CA266947NCI NIH HHS P01 CA087969NCI NIH HHS P30 CA076292NCI NIH HHS R01 CA124515NCI NIH HHS R01 CA184185NCI NIH HHS R01 CA278907NCI NIH HHS R01 CA297896NCI NIH HHS R21 CA276205
6 · The paper itself

Abstract

Many epithelial cancers orchestrate prognostically significant intratumoral tertiary lymphoid structures (TLSs), yet the mechanisms behind their antitumor activity remain unclear. Here we show that intratumoral TLS in ∼14% of human high-grade serous ovarian cancer (HGSOC) harbor highly oligoclonal B cells expressing IgA or IgG, which are not found in distant tumor regions. By engineering a recombinant antibody with the dominant B cell receptor (BCR) sequence from a mature ovarian cancer TLS, we inhibited the growth of the corresponding autologous tumor

Indexed as

B cells in cancercancer antibodiesimmuno-oncologyovarian cancertertiary lymphoid structure

Identifiers

PMID42472098
PMCPMC13380442

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.